Generic Name and Formulations:
Benztropine mesylate 0.5mg, 1mg, 2mg; scored tabs.
Various generic manufacturers
Indications for Benztropine:
Adjunct in Parkinsonism, drug-induced extrapyramidal disorders.
Parkinsonism: initially 0.5–1mg at bedtime. May increase by 0.5mg at 5–6 day intervals; max 6mg daily. Extrapyramidal disorders: 1–4mg 1–2 times daily. Acute dystonic reactions: 1–2mg IM or IV.
See Contraindications. Use cautiously in older children.
Children <3yrs old.
Tardive dyskinesia: not recommended. Narrow-angle glaucoma. Tachycardia. Psychosis. Prostatic hypertrophy. GI or GU obstruction. Chronically ill. Alcoholics. CNS disease. Exposure to extreme heat. Elderly. Pregnancy.
Paralytic ileus, hyperthermia, heat stroke with phenothiazines, tricyclic antidepressants. Antagonizes psychotropics.
Anticholinergic and antihistaminic effects, weakness, confusion, anhidrosis, excitement, GI upset, depression, lethargy, heat stroke, dysuria, toxic psychosis, rash.
Tabs formerly known under the brand name Cogentin.
Tabs—contact supplier; Amps—(5 x 2mL)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|